Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Patient Experience Data: US FDA Guidance Offers Other Ways To Share

Executive Summary

Beyond submitting proposed guidances to FDA, stakeholders may develop patient registries, conduct natural history studies, and establish partnerships to help advance patient-focused drug development, agency suggests.

Advertisement

Related Content

Patient-Focused Drug Development: US FDA 'Needs To Be Brave,' Tell Sponsors What Works Best
Patient Experience Data: US FDA’s Evidentiary Standards Should Reflect Intended Use
There's More To Patient Experience Data Submissions Than Just Guidances, Advocates Tell US FDA
Disease-Specific Guidances Reflect US FDA's 'Nimble, Collaborative, Patient-Focused' Approach
Duchenne Muscular Dystrophy: FDA Supports Broader Outcome Measures, Biomarkers

Topics

Advertisement
UsernamePublicRestriction

Register

PS124463

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel